A Phase 2 interventional study of diclofenac sodium and dexotc in Otitis Externa, sponsored by Sieff Medical Center. Terminated at 1 site in Israel. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-04-20.
Sponsored by Sieff Medical Center · Phase 2, Interventional, and Treatment
Voltaren being a Non-steroidal anti-inflammatory drug (NSAID) drug may be used as a single drug therapy in otitis externa being both therapeutic and analgesic thus reducing consumption of oral analgesia.
anticipated advantages are: reduction of inflammation and edema, no fungal overpopulation- when steroids are employed, contains boric acid as an ingredient, high safety profile, can be switched to antibiotic therapy later, can be used in conjunction wit steroids
Exclusion Criteria:
voltaren ophta
Drug: diclofenac sodium
dexotic
Drug: dexotc
topical solution used in ear 5 drops 8 3/day
Also known as: voltaren ophta
aural drops
Also known as: dexotic
reducing oral analagestic use
Time frame: 1 week
adding an alternative treatment for otitis externa
Time frame: 1 week
This study is terminated, as verified in Apr 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.